10 drugmakers team up to improve testing process

by The Associated Press

(AP)—Pharmaceutical industry heavyweights are teaming up to address a challenge that's long vexed drugmakers: how to improve the way experimental drugs are tested so they can get approved, and reach patients, faster.

Ten top U.S. and European drugmakers have started a , called TransCelerate BioPharma, to collaborate on the problem.

across the industry has been declining, with thousands of potential drugs failing for every one approved, but testing costs keep rising.

The new group will develop strategies to make it easier and quicker to set up and run of experimental drugs.

Initial participants include Pfizer, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, Abbott, GlaxoSmithKline, AstraZeneca, Sanofi, Boehringer Ingelheim and Genentech.

The group's CEO, Garry Neil, says he expects to have initial results next summer.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Lilly, Boehringer collaborate on diabetes drugs

Jan 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

FDA weighs approval of psychiatric drugs for kids

Jun 05, 2009

(AP) -- Three blockbuster psychiatric drugs currently approved for adults also appear to work in adolescents, though federal health officials have concerns about exposing younger patients to the drugs' side effects.

FDA links once-promising pain drugs to bone decay

Mar 08, 2012

Some of the world's largest drugmakers will face an uphill battle next week in their bid to revive a class of experimental arthritis drugs that have been sidelined by safety concerns for nearly two years.

Recommended for you

Determine patient preferences by means of conjoint analysis

21 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments